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Niek F. Casteleijn, MD,1 Jaime D. Blais, PhD,2 Arlene B. Chapman, MD, PhD,3
Frank S. Czerwiec, MD, PhD,2 Olivier Devuyst, MD, PhD,4 Eiji Higashihara, MD,5
Anna M. Leliveld, MD, PhD,6 John Ouyang, PhD,2 Ronald D. Perrone, MD,7
Vicente E. Torres, MD, PhD,8 and Ron T. Gansevoort, MD, PhD,1 on behalf of the
TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant
Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators*
Background: Kidney pain is a common complication in patients with autosomal dominant polycystic kidney
disease (ADPKD), and data from the TEMPO 3:4 trial suggested that tolvaptan, a vasopressin V2 receptor
antagonist, may have a positive effect on kidney pain in this patient group. Because pain is difficult tomeasure, the
incidence of kidney pain leading to objective medical interventions was used in the present study to assess pain.
Study Design: Secondary analysis from a randomized controlled trial.
Setting & Participants: Patients with ADPKD with preserved kidney function.
Intervention: Tolvaptan or placebo.
Outcomes: Kidney pain events defined by objective medical interventions.
Measurements: Kidney pain events were recorded and independently adjudicated. Incidence of a first
kidney pain event was assessed overall and categorized into 5 subgroups according to severity.
Results: Of 1,445 participating patients (48.4% women; mean age, 39 6 7 [SD] years; mean estimated
glomerular filtration rate, 81 6 22 mL/min/1.73 m2; median total kidney volume, 1,692 [IQR, 750-7,555] mL),
50.9% reported a history of kidney pain at baseline. History of urinary tract infections, kidney stones, or he-
maturia (all P , 0.001) and female sex (P, 0.001) were significantly associated with history of kidney pain.
Tolvaptan use resulted in a significantly lower incidence of kidney pain events when compared to placebo:
10.1% versus 16.8% (P , 0.001), with a risk reduction of 36% (HR, 0.64; 95% CI, 0.48-0.86). The reduction in
pain event incidence by tolvaptan was found in all groups irrespective of pain severity and was independent of
predisposing factors (P for interaction . 0.05). The effect of tolvaptan was explained at least in part by a
decrease in incidence of urinary tract infections, kidney stones, and hematuria when compared to placebo.
Limitations: Trial has specific inclusion criteria for total kidney volume and kidney function.
Conclusions: Tolvaptan decreased the incidence of kidney pain events independent of patient character-
istics predisposing for kidney pain and possibly in part due to reductions in ADPKD-related complications.
Am J Kidney Dis. 69(2):210-219. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
INDEXWORDS: Autosomal dominant polycystic kidney disease (ADPKD); pain; tolvaptan; vasopressin; acute
kidney pain event; TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic
Kidney Disease and Its Outcomes) 3:4; pain severity; analgesic.1Department of Nephrology, University Medical
ningen, University of Groningen, Groningen, the
; 2Otsuka Pharmaceutical Development & Commer-
Inc, Rockville, MD; 3Division of Nephrology, Emory
School of Medicine, Atlanta, GA; 4Institute of
Zurich Center for Integrative Human Physiology,
of Zurich, Zurich, Switzerland; 5Department of
yorin University School of Medicine, Mitaka, Japan;
t of Urology, University Medical Center Groningen,
f Groningen, Groningen, the Netherlands; 7Division
gy, Tufts Medical Center, Tufts University School of
Boston, MA; and 8Division of Nephrology and
n, Department of Internal Medicine, Mayo Clinic,
MN.
st of the TEMPO 3:4 Investigators is given in the
al Appendix of Torres et al.5
March 24, 2016. Accepted in revised form August 8,
nally published online November 14, 2016.
Because the Editor-in-Chief and Deputy Editor recused them-
selves from consideration of this article, the peer-review and
decision-making processes were handled entirely by a Co-Editor
(Wolfgang C. Winkelmayer, MD, ScD, MPH) who served as
Acting Editor-in-Chief. Details of the journal’s procedures for
potential editor conﬂicts are given in the Information for Authors
& Journal Policies.
Address correspondence to Ron T. Gansevoort, MD, PhD,
Expertise Center for Polycystic Kidney Diseases, Department of
Nephrology, University Medical Center Groningen, University of
Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands.
E-mail: r.t.gansevoort@umcg.nl
 2016 The Authors. Published by Elsevier Inc. on behalf of the
National Kidney Foundation, Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
0272-6386
http://dx.doi.org/10.1053/j.ajkd.2016.08.028
Am J Kidney Dis. 2017;69(2):210-219
Tolvaptan and Kidney Pain in ADPKDPain is a common complication in patients withautosomal dominant polycystic kidney disease
(ADPKD). It is a symptom that is often reported early
in the disease course and that sometimes can be se-
vere and difﬁcult to manage and adversely affect a
patient’s quality of life.1-3 Acute pain in patients with
ADPKD can be caused by cyst hemorrhage, infection,
and kidney stones, which are often accompanied by
hematuria. When pain is present longer than 4 to 6
weeks, it is typically classiﬁed as chronic pain, which
has a reported prevalence as high as 60%.4
The TEMPO (Tolvaptan Efﬁcacy and Safety in
Management of Autosomal Dominant Polycystic
Kidney Disease and Its Outcomes) 3:4 trial demon-
strated the renoprotective effects of tolvaptan treat-
ment in a randomized controlled clinical trial setting.5
During 3 years’ follow-up, tolvaptan, a vasopressin
V2 receptor antagonist, reduced the annual rate of
growth in total kidney volume (TKV) from 5.5% to
2.8% (P , 0.001) and the annual rate of estimated
glomerular ﬁltration rate (eGFR) decline from 23.70
to 22.72 mL/min/1.73 m2 (P , 0.001) compared to
placebo.5 This trial also demonstrated a reduction in
clinical progression as assessed by its key secondary
composite end point through a reduction of ADPKD-
related clinical events. This outcome was driven by 2
components of the composite: time to decline in
kidney function and time to clinically signiﬁcant
kidney pain events.5
In the present study, we explored this last ﬁnding
more closely. We characterized what constituted a
“clinically signiﬁcant kidney pain event” by objec-
tively examining the intensity of medical in-
terventions used to deﬁne them. We also investigated
the association of ADPKD clinical characteristics
(such as history of kidney pain, infection, kidney
stones, or hematuria at baseline) with the incidence of
acute kidney pain events during the 3-year trial.
Furthermore, we analyzed the effect of tolvaptan use
on incidence of kidney pain events and explored
whether new pain events were associated with base-
line patient characteristics and the possible mecha-
nisms by which tolvaptan reduced their incidence.
METHODS
Study Design and Patients
The present study was performed as a post hoc exploratory
analysis of the TEMPO 3:4 trial, a prospective, blinded, ran-
domized, placebo-controlled trial in patients with diagnosed
ADPKD (ClinicalTrials.gov study number NCT00428948). Pa-
tients were enrolled at 129 sites worldwide during January 2007 to
January 2009. Inclusion criteria were age 18 to 50 years with a
diagnosis of ADPKD, TKV measured by magnetic resonance
imaging $ 750 mL, and creatinine clearance estimated by the
Cockcroft-Gault formula $60 mL/min. Exclusion criteria
included, among others, concomitant illnesses likely to confound
end point assessments, such as diabetes mellitus, and prior kidneyAm J Kidney Dis. 2017;69(2):210-219surgery. The institutional review board or ethics committee at each
site approved the protocol. Written informed consent was obtained
from all participants. Details of the study protocol6 and the pri-
mary study results5 have been published previously. This report
has been prepared in accordance with the CONSORT (Consoli-
dated Standards of Reporting Trials) 2010 Statement.7
Study Treatment
Patients were randomly assigned to receive tolvaptan or placebo
(2:1). Tolvaptan dosing was started at 45 mg AM/15 mg PM (daily
split dose) and increased weekly to 60/30 mg and 90/30 mg if
tolerated. Patients remained on the highest tolerated dose for 36
months.
Study Assessments and Deﬁnitions
Evaluations were performed at baseline, every 4 months during
treatment, and twice for 2 to 6 weeks after completion of treatment
at 36 months and included interviews, examinations, vital sign
measurements, and blood and trough spot morning urine samples.
TKV was assessed using standardized kidney magnetic resonance
imaging at baseline and months 12, 24, and 36 or at early with-
drawal. In addition, height-adjusted TKV was calculated as TKV
in milliliters divided by height in meters. Serum creatinine level
was reported to 2 decimal points and used to estimate GFR
(applying the CKD-EPI [Chronic Kidney Disease Epidemiology
Collaboration] equation).8
At baseline, a standardized interview was performed to gather
information about demographic characteristics and medical his-
tory, including information for prior kidney pain. Incidence of
acute kidney pain during follow-up was a component of the
composite secondary efﬁcacy end point, which assessed kidney
pain events requiring medical intervention and that required
documentation of clinical signs and symptoms that pain was
kidney related (ie, ﬂank tenderness or evidence of cystic expansion
or hemorrhage). The investigator’s clinical judgment was required
to arbitrate whether the level of pain met the deﬁnition of end
point, which required clinically signiﬁcant kidney pain necessi-
tating pharmacologic treatment or invasive intervention. Pain was
a priori categorized according to the intensity of intervention into 5
groups: mild, prescription of acetaminophen; moderate, prescrip-
tion of other non-narcotic analgesics; moderately severe, pre-
scription of non-narcotic analgesic and limitation in physical
activity; severe, prescription of narcotic analgesics; most severe,
need for hospitalization and/or invasive intervention. Events were
assessed by an independent adjudication committee blinded for
treatment allocation. Finally, the incidence of urinary tract infec-
tion, kidney stones, and hematuria was assessed as a composite
score and separately. Of note, the initial TEMPO 3:4 trial publi-
cation provided data for these events only when reported as
(serious) adverse events, whereas in the present study, all clinically
signiﬁcant pain-related adverse events are taken into account.
Study Outcomes
The primary end point in this study was the effect of tolvaptan
use on incidence of acute kidney pain events compared to placebo.
Second, we investigated: (1) the association of ADPKD clinical
characteristics (such as history of kidney pain, infection,
kidney stones, or hematuria at baseline) with the incidence of acute
kidney pain events during the 3-year trial, (2) whether new acute
kidney pain events were associated with baseline patient charac-
teristics, and (3) the possible mechanisms by which tolvaptan
reduced their incidence.
Statistical Analyses
Baseline characteristics were calculated for participants with
and without a history of kidney pain separately. Normally
distributed variables are expressed as mean 6 standard deviation,211
Casteleijn et alwhereas non–normally distributed variables are given as median
(interquartile range [IQR]). Differences in baseline characteristics
between patients with and without a history of kidney pain were
calculated with c2 test for categorical data, and for continuous
data, with t test or Mann-Whitney U test in case of non–normally
distributed data. To investigate whether baseline patient charac-
teristics correlated with a history of kidney pain, univariate and
multivariate logistic regression analyses were performed. The
multivariate logistic analyses were subsequently adjusted for sex,
age, height-adjusted TKV, and eGFR to investigate the impact of
patient characteristics that predispose for kidney pain events that
are not associated with disease severity. TKV, height-adjusted
TKV, and albumin-creatinine ratio were log2-transformed to
fulﬁll the requirement of normal distribution of the residuals for
regression analysis.
In the placebo and tolvaptan groups, the overall incidence of a
ﬁrst acute kidney pain event during the 3-year trial was assessed in
the intention-to-treat population, and the incidence of acute kidney
pain events was subdivided in 5 categories named by pain severity
and deﬁned by the medical intervention used to treat the event.
Cox proportional hazards regression analyses were performed to
investigate whether baseline characteristics associated with the
ﬁrst acute kidney pain event during the trial, with censoring of
patients lost to follow-up or stopping study medication. First,
unadjusted hazard ratios (HRs) with 95% conﬁdence intervals
were calculated. Second, we calculated multivariate-adjusted HRs,
which were adjusted for sex, age, height-adjusted TKV, and eGFR
to investigate the impact of patient characteristics that predispose
for acute kidney pain events that are not associated with disease
severity. The number needed to treat to prevent 1 acute kidney
pain event was calculated based on the cumulative event pro-
portions. In addition, we investigated the effect of tolvaptan on
incidence of acute kidney pain events in the overall TEMPO 3:4Screene
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Figure 1. Patient enro
212trial population and in subgroups according to baseline charac-
teristics, and P for interaction by subgroup was calculated. Last,
the effect of tolvaptan on renal complications known to cause pain
was investigated.
Two sensitivity analyses were performed. First, the effect of
tolvaptan on incidence of acute kidney pain events was investi-
gated as time to ﬁrst occurrence of each speciﬁc category of
intervention/pain severity instead of as cumulative incidence.
Second, the effect of tolvaptan was investigated including multiple
acute kidney pain events per patient. All analyses were performed
with SAS, version 9.2 statistical software (SAS Institute Inc), and
2-sided P, 0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
Baseline Characteristics
A total of 1,445 patients with ADPKDwere enrolled
in the TEMPO 3:4 trial (Fig 1). Mean age was 39 6 7
years, and 48.4% were women (Table 1). By protocol,
patients had preserved kidney function, with mean
eGFR of 81 6 22 mL/min/1.73 m2 and median TKV
of 1,692 (IQR, 750-7,555) mL. At baseline, 50.9% of
participants reported having a history of kidney pain.
Patient characteristics were stratiﬁed according to
those with or without a history of kidney pain
(Table 1). A history of urinary tract infection, kidney
stones, or hematuria was associated with having a
history of kidney pain. Other signiﬁcant associations
included female sex, smaller body size, and lowerd: 
nts
ed: 
nts
Patients excluded: 677
539 Did not meet inclusion criteria
45 Declined to participate
102 Other
Placebo: 
484 patients
Discontinued study: 67
24 Adverse events
30 Withdrew consent
8 Lost to follow-up
4 Withdrawn by investigator
1 Protocol deviation
Completed the trial: 
417 patients (86.2%)
Included in 
present study: 
484 patients (100%)
llment and outcomes.
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Table 1. Baseline Characteristics of TEMPO 3:4 Trial
Participants Stratified According to History of Kidney Pain
History of Kidney Pain
PYes (n 5 735) No (n 5 710)
Female sex 389 (52.9) 310 (43.7) ,0.001
Age, y 38.86 7.0 38.4 6 7.2 0.2
Height, cm 172.96 10.1 174.26 10.1 0.01
Weight, kg 79.3 6 18.4 79.0 6 18.1 0.9
BMI, kg/m2 26.46 5.3 25.9 6 4.8 0.2
History of
UTI 307 (41.9) 147 (20.7) ,0.001
Hematuria 318 (43.3) 185 (26.1) ,0.001
Kidney stones 196 (26.7) 100 (14.1) ,0.001
Liver cysts 450 (61.4) 412 (58.0) 0.2
Systolic BP,
mm Hg
128.66 13.3 128.56 13.7 0.9
Diastolic BP,
mm Hg
82.66 9.5 82.4 6 10.0 0.9
Use of BP-
lowering drug
529 (72.0) 510 (71.8) 0.9
Presence of
hypertension
609 (82.9) 583 (82.1) 0.7
eGFR, mL/min/
1.73 m2
82.4 6 21.8 80.8 6 21.4 0.2
TKV, mL 1,6946 899 1,6906 912 0.7
hTKV, mL/m 976 6 501 967 6 508 0.5
Urine osmolality,
mOsm/kg
493.46 175.5 510.4 6 181.8 0.04
ACR, mg/mmol 3.1 [1.2-8.1] 3.3 [1.1-8.8] 0.2
Note: Values for categorical variables are given as number
(percentage); values for continuous variables, as mean 6
standard deviation or median [interquartile range].
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass
index; BP, blood pressure; eGFR, estimated glomerular filtration
rate; hTKV, height-adjusted total kidney volume; TEMPO, Tol-
vaptan Efficacy and Safety in Management of Autosomal
Dominant Polycystic Kidney Disease and Its Outcomes; TKV,
total kidney volume; UTI, urinary tract infection.
Tolvaptan and Kidney Pain in ADPKDurine osmolality, although for the last 2 variables, the
absolute difference between patients with and without
a history of kidney pain was small and likely not
clinically relevant. Each of these characteristics
remained signiﬁcant when adjusted for sex, age,
height-adjusted TKV, and eGFR (Table S1, available
as online supplementary material). No associations
were found for history of kidney pain and eGFR, TKV,
or height-adjusted TKV. Of the 1,445 participating
patients, 484 were randomly assigned to placebo, and
961, to tolvaptan, of whom 49.4% and 51.6% had a
history of kidney pain, respectively (P 5 0.4). No
signiﬁcant differences in patient characteristics were
observed between treatment groups when comparing
participants with or without a history of pain.
Kidney Pain Events Over 3 Years in Placebo Group
In the placebo group, 16.7% of patients had an
episode of kidney pain during the 3-year trial. AAm J Kidney Dis. 2017;69(2):210-219history of urinary tract infection, kidney stones, he-
maturia, or kidney pain and female sex tended to be
associated with incident kidney pain events (Table 2).
After adjusting for age, sex, height-adjusted TKV,
and eGFR, these factors were signiﬁcantly associated
with kidney pain events during the study, except for a
history of urinary tract infection (Table 2). No asso-
ciation was found between baseline TKV, height-
adjusted TKV, or eGFR with kidney pain events
during follow-up; neither crude analysis nor analysis
after multivariate adjustment for covariates.
Effect of Tolvaptan on Incidence of Kidney
Pain Events
In contrast to the 16.7% incidence reported for
patients in the placebo group, 10.1% of the tolvaptan
group had clinically signiﬁcant kidney pain during the
3-year trial. Identiﬁed risk factors for acute kidney
pain events in the placebo group, for example, history
of kidney stones, hematuria, or kidney pain and fe-
male sex, tended also to be associated with incident
kidney pain events in the tolvaptan group (Table S2).
Tolvaptan use was associated with a signiﬁcantly
lower incidence of ﬁrst kidney pain events when
compared to placebo (P , 0.001), with a risk reduc-
tion of 36% (HR, 0.64; 95% conﬁdence interval,
0.48-0.86; Table 3). The difference in cumulative
incidence of patients having a kidney pain event be-
tween the tolvaptan and placebo groups increased
over time (Fig 2). We analyzed the effects of tol-
vaptan on the incidence of kidney pain events among
various subgroups based on speciﬁc baseline charac-
teristics (Fig 3). No interactions were found between
the effect of tolvaptan on kidney pain and patient
characteristics of disease severity, characteristics
predisposing for worse renal prognosis, or character-
istics predisposing for kidney pain (P for interaction
all nonsigniﬁcant). When pain was deﬁned more
strictly, similar efﬁcacy of tolvaptan was noted
(Table 3). The number needed to treat to prevent 1
pain event ranged from 35 patients when taking any
pain event into account (prescription of acetamino-
phen or worse) to 384 patients when taking only the
most severe pain category into account (hospitaliza-
tion or invasive intervention; Table 3).
Last, we investigated whether the mechanism of
tolvaptan in reducing kidney pain events could be
elucidated. Patients with ADPKD having an acute
kidney pain event had a similar TKV growth rate
compared with patients with ADPKD who did not
have such an event. This was the case for patients in
the placebo group and those in the tolvaptan group
(Table 4). The signiﬁcant reduction in number of
participants having reported kidney pain was matched
by similar reductions in the incidence of renal com-
plications likely to cause such pain in ADPKD, such213
Table 2. Associations of Baseline Characteristics With First Kidney Pain Events During 3 Years’ Follow-up in the 484 Placebo-Treated
Patients in TEMPO 3:4 Trial
Crude
Adjusted for Age, Sex, hTKV,
eGFR
HR (95% CI) P HR (95% CI) P
Female sex 2.01 (1.27-3.20) 0.003 2.15 (1.33-3.45) 0.002
Age, per 5 y older 0.97 (0.83-1.13) 0.7 0.99 (0.83-1.18) 0.9
Height, per 5 cm greater 0.85 (0.75-0.96) 0.01 0.92 (0.78-1.09) 0.3
Weight, per 5 kg greater 0.95 (0.89-1.02) 0.1 0.98 (0.91-1.06) 0.6
BMI, per 1 kg/m2 greater 1.00 (0.95-1.04) 0.8 1.00 (0.95-1.05) 0.9
History of
Kidney pain 2.24 (1.40-3.58) ,0.001 2.15 (1.33-3.48) 0.002
UTI 2.00 (1.28-3.12) 0.002 1.54 (0.94-2.51) 0.08
Hematuria 1.55 (0.99-2.43) 0.1 1.75 (1.10-2.79) 0.01
Kidney stones 1.63 (1.01-2.64) 0.04 1.84 (1.13-3.00) 0.01
Systolic BP, per 5 mm Hg greater 1.00 (0.92-1.09) 0.9 1.03 (0.95-1.12) 0.5
Diastolic BP, per 5 mm Hg greater 1.08 (0.95-1.21) 0.2 1.12 (0.99-1.26) 0.1
Use of BP-lowering drug 0.88 (0.54-1.44) 0.6 0.93 (0.55-1.58) 0.8
Presence of hypertension 1.20 (0.63-2.27) 0.6 1.36 (0.69-2.69) 0.4
eGFR, per 5 mL/min/1.73 m2 greater 1.00 (0.96-1.06) 0.8 1.00 (0.94-1.06) 0.9
Log TKV, per doubling of TKV in mL 0.96 (0.67-1.37) 0.8 0.14 (0.76-1.73) 0.3
Log hTKV, per doubling of hTKV in mL/m 1.02 (0.71-1.45) 0.9 1.17 (0.77-1.75) 0.5
Urine osmolality, per 50 mOsm/kg greater 0.98 (0.92-1.04) 0.4 0.98 (0.92-1.04) 0.5
Log ACR, per doubling of ACR in mg/mmol 1.09 (0.95-1.25) 0.2 1.08 (0.93-1.26) 0.3
Note: In multivariate analyses, risks were adjusted for age, sex, hTKV, and eGFR. In case the association between eGFR and first
acute kidney pain event was investigated, the variable eGFR was not incorporated twice in the model.
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; CI, confidence interval; eGFR, estimated
glomerular filtration rate; HR, hazard ratio; hTKV, height-adjusted total kidney volume; TEMPO, Tolvaptan Efficacy and Safety in
Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes; TKV, total kidney volume; UTI, urinary tract
infection.
Casteleijn et alas urinary tract infections and kidney stones, and
bouts of macroscopic hematuria that can be detected
in patients having cyst ruptures and bleeds (infections,
11.1% vs 15.3% [P 5 0.02]; kidney stones, 2.2% vs
3.5% [P , 0.001]; hematuria, 8.0% vs 14.3%
[P , 0.001]; any of the 3 aforementioned, 18.9% vs
28.7% [P , 0.001]). Irrespective of treatment arm,
patients with kidney pain events had a higher inci-
dence of these disease-related complications than
those not having pain events.
Sensitivity Analyses
When pain events were analyzed by subgroup of
pain severity instead of as cumulative incidence, risk
reduction was observed for tolvaptan across all sub-
groups. Of note, relative risk reductions did not reach
formal statistical signiﬁcance in all subgroups, likely
due to the small number of patients per pain category
(Table S3). Sensitivity analysis focused on multiple-
event analyses yielded essentially the same result as
the primary time-to-ﬁrst-event analysis (Table S4).
DISCUSSION
Our study had a cross-sectional and a longitudinal
part. In the cross-sectional analysis of baseline data of214the TEMPO 3:4 trial, history of kidney pain was
observed in 50.9% of participants. Acute kidney pain
events in patients with ADPKD are often caused by
urologic complications such as urinary tract in-
fections, kidney stones, and cyst bleeding and rupture.
The latter 2 are clinically diagnosed by bouts of
macroscopic hemorrhage.1,2,4,9 In support of this, we
found independent associations between history of
kidney pain and history of urinary tract infection,
kidney stones, and hematuria. Three prior studies
have investigated the prevalence of pain in patients
with ADPKD in a cross-sectional setting.10-12 The
largest of these studies was performed by Miskulin
et al10 using baseline data from 1,043 patients with
ADPKD participating in the HALT2Polycystic
Kidney Disease (PKD) studies. The authors described
that pain is an early symptom in the course of
ADPKD.10 The percentage of participants with a
history of pain events in HALT-PKD was similar to
the percentage of participants in the TEMPO 3:4
trial.5,10 Furthermore, they found that pain prevalence
was inversely correlated with eGFR, but only in pa-
tients at lower eGFRs (,45 mL/min/1.73 m2).10 In
our study, we did not ﬁnd such an association, which
may be explained because TEMPO 3:4 enrolledAm J Kidney Dis. 2017;69(2):210-219
Table 3. Cumulative Incidence of Patients Having a Kidney Pain
Event During 3 Years’ Follow-up According to Severity of Pain
as Scored by Intensity of Intervention
Pain
Severity
Pain Events/
100 person-y
F/U
HR
(95% CI) NNT P
Mild or worse
(overall)
Tolvaptan 5.09 0.64 (0.48-0.86) 35 ,0.001
Placebo 8.09
Moderate or worse
Tolvaptan 4.05 0.62 (0.45-0.86) 39 0.01
Placebo 6.74
Moderately
severe or
worse
Tolvaptan 2.94 0.67 (0.45-1.00) 64 0.05
Placebo 4.55
Severe or worse
Tolvaptan 2.31 0.74 (0.46-1.18) 94 0.2
Placebo 3.40
Most severe
Tolvaptan 0.21 0.22 (0.04-1.14) 384 0.07
Placebo 0.38
Abbreviations and Definitions; CI, confidence interval; F/U,
follow-up; HR, hazard ratio; mild, prescription of acetaminophen;
moderate, prescription of non-narcotic analgesics; moderately
severe, limitation in physical activity; most severe, need for
hospitalization and/or invasive intervention; NNT, number
needed to treat; severe, prescription of narcotic analgesics.
Tolvaptan and Kidney Pain in ADPKDpatients with relatively preserved kidney function
(estimated creatinine clearance . 60 mL/min).5 In the
other 2 studies (involving 219 and 152 patients with
ADPKD, respectively), pain was assessed in patientsC
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Am J Kidney Dis. 2017;69(2):210-219across a broad range of kidney function, including
patients on dialysis therapy.11,12 These studies found
that pain was positively correlated with the physical
component score of health-related quality-of-life
questionnaires, but they did not identify potential risk
factors for kidney pain. We found that female sex was
signiﬁcantly associated with history of kidney pain,
even when adjusted for height, age, and disease
severity. To our knowledge, no other study has spe-
ciﬁcally reported this association. However, the study
by Miskulin et al10 shows that a history of pain was
also reported more by female compared with male
patients with ADPKD. A history of back pain, for
instance, was reported by 56.8% versus 45.1%,
respectively.10 Medical and invasive treatments for
pain were also more frequent in female patients.
Whether this sex difference is speciﬁc for ADPKD is
not clear. Several reviews have concluded, for
instance, that in the general population, pain is more
frequently reported by women than by men.13,14 It has
been suggested that an interaction of biological (eg,
sex hormones), psychological (eg, coping strategies),
and sociocultural (eg, femininity) factors may
contribute to this sex difference.13
In the longitudinal part of our study, 16.8% of
patients in the placebo group reported acute kidney
pain events during the 3-year trial. This is the ﬁrst trial
to prospectively investigate the incidence of such
events in ADPKD. We found that history of kidney
pain, kidney stones, and hematuria and female sex
were associated with incident kidney pain. Therefore,
our study shows in a cross-sectional and a longitu-
dinal setting that these factors are associated with
acute kidney pain.20 24 28 32 36 40
w-up (months)
P-value < 0.001
Tolvaptan
Placebo
ain event in tolvaptan- (blue solid line, n5 97) and placebo- (red
aptan use was associated with a significantly lower incidence of
ction of 36% (hazard ratio [HR], 0.64; 95% confidence interval,
ional hazards indicated that the HR was constant over time
215
Subgroups N n HR (CI 95%) P P for interaction
Overall 1445 178 0.64 (0.48-0.86) <0.001
Male 746 69 0.75 (0.46-1.20) 0.2 0.4
Female 699 109 0.59 (0.40-0.85) 0.01
Age < 35 years 366 41 0.38 (0.21-0.70) 0.002 0.06
Age ≥ 35 years 1079 137 0.75 (0.54-1.06) 0.1
Height < 170 cm 518 77 0.65 (0.42-1.03) 0.1 0.9
Height ≥ 170 cm 925 98 0.63 (0.42-0.93) 0.02
BMI < 25 kg/m2 684 83 0.56 (0.36-0.86) 0.01 0.4
BMI ≥ 25 kg/m2 761 95 0.73 (0.48-1.09) 0.1
History of renal pain 735 129 0.72 (0.51-1.02) 0.1 0.1
No history of renal pain 710 46 0.43 (0.24-0.77) 0.02
History of UTI 454 76 0.54 (0.34-0.84) 0.01 0.2
No history of UTI 989 102 0.77 (0.52-1.14) 0.2
History of hematuria 503 75 0.61 (0.39-0.97) 0.03 0.8
No history of hematuria 941 103 0.66 (0.45-0.97) 0.04
History of renal stones 296 54 0.75 (0.44-1.28) 0.3 0.6
No history of renal stones 1148 124 0.63 (0.44-0.89) 0.01
Presence of liver cysts 862 124 0.56 (0.39-0.79) 0.001 0.1
No presence of liver cysts 581 54 0.91 (0.53-1.57) 0.7
eGFR < 80 mL/min/1.73m2 698 84 0.66 (0.43-1.02) 0.1 0.9
eGFR ≥ 80 mL/min/1.73m2 742 93 0.64 (0.43-0.97) 0.03
TKV < 1500 mL 753 84 0.52 (0.34-0.79) 0.002 0.2
TKV ≥ 1500 mL 692 94 0.79 (0.52-1.19) 0.3
hTKV < 800 mL/m 639 68 0.53 (0.33-0.85) 0.01 0.3
hTKV ≥ 800 mL/m 803 110 0.72 (0.50-1.06) 0.1
Figure 3. Effect of tolvaptan on first acute kidney pain events versus placebo during 3 years’ follow-up in the overall study popu-
lation and in subgroups according to baseline characteristics. Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtra-
tion rate; HR, hazard ratio; hTKV, height-adjusted total kidney volume; N, number of participants; n, number of events; TKV, total
kidney volume; UTI, urinary tract infection.
Casteleijn et alIn ADPKD, it is generally assumed that large
kidney volumes play a role in causing pain. Interest-
ingly, in this study, neither TKV nor height-adjusted
TKV associated with acute kidney pain at baseline
(Table 1) or during the trial (Table 2). These results
are supported by ﬁndings in the 539 patients in the
study by Miskulin et al10 for whom magneticTable 4. Change in TKV, Kidney Function, and Cumulative Inciden
Pain in Placebo and Tolvaptan Gro
Placebo
Overall Pain No Pain
No. of patients 484 81 403
Change in TKV, % per y 5.6 6 5.3 6.5 6 6.9 5.4 6 4.9
Change in eGFR,
mL/min/1.73 m2 per y
23.76 5.8 23.86 4.8 23.76 5.9
Incidence of
UTI 15.3 24.7 13.4
Hematuria 14.3 32.1 10.7
Kidney stones 3.5 12.4 1.7
Any of the above 28.7 51.2 24.1
Note: Data are given overall and separately for patients having a
values for categorical variables are given as percentage; values for
Abbreviations: eGFR, estimated glomerular filtration rate; TKV, to
216resonance images were available. In these patients, no
relationship was found between TKV and pain except
in patients with very large kidneys. The authors pro-
posed that cyst number, size, or location may be more
important than TKV in causing pain. However, in-
formation for these variables was not available in their
study and thus needs additional investigation. Othersce of Renal Complications Known to be Associated With Acute
ups During 3 Years’ Follow-up
Tolvaptan
P Overall Pain No Pain P
961 97 864
0.2 2.86 5.7 2.86 5.0 2.86 5.7 0.9
0.4 22.3 6 8.7 23.1 6 7.9 22.26 8.8 0.02
0.02 11.1 16.5 10.5 0.1
,0.001 8.0 21.7 6.5 ,0.001
,0.001 2.2 9.3 1.4 ,0.001
,0.001 18.9 41.2 16.4 ,0.001
nd not having kidney pain events. Unless otherwise indicated,
continuous variables, as mean 6 standard deviation.
tal kidney volume; UTI, urinary tract infection.
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Tolvaptan and Kidney Pain in ADPKDhave suggested that the combined volume of the
kidneys and liver is the major determinant of
ADPKD-related symptoms, including pain.11,15
However, total liver volumes were not measured in
TEMPO 3:4, so we can neither conﬁrm nor reject this
hypothesis.
During the trial, 10.1% of the tolvaptan group had
events of clinically signiﬁcant acute kidney pain
compared to 16.8% of the placebo group, indicating a
relative risk reduction by tolvaptan of 36% (Table 3).
This pain incidence-lowering effect was found in all
subgroups deﬁned by intervention and was indepen-
dent of baseline clinical characteristics shown to
predispose for kidney pain. We attempted to deter-
mine a mechanism for the kidney pain-lowering effect
of tolvaptan. It was hypothesized that patients with a
lower TKV growth rate would have a lower incidence
of kidney pain events because tolvaptan reduced the
rate of TKV growth by 49%.5 However, per-
treatment-arm TKV growth rate was similar in pa-
tients having and not having a kidney pain event
(Table 4). This ﬁnding, in combination with the lack
of association between TKV and history of kidney
pain at baseline (Table 1) and incident pain events
during the trial (Table 2), suggests that the effect of
tolvaptan on incidence of kidney pain events may not
be primarily related to its effect on TKV growth rate.
Another mechanism may be related to a drug-
related decrease in the incidence of renal complica-
tions that are known to be associated with acute
kidney pain events (eg, a reduction in incidence of
urinary tract infections, kidney stones, and cyst
hemorrhage and ruptures [assessed as bouts of he-
maturia]). At baseline and during the trial, associa-
tions were found between these disease-related
complications and history or incidence of kidney
pain. Importantly, tolvaptan lowered the incidence of
these complications compared to placebo: urinary
tract infections, lowered by 27% (P 5 0.02); kidney
stones, lowered by 37% (P , 0.001); and hematuria,
lowered by 44% (P , 0.001; Table 4). In addition, a
signiﬁcantly higher incidence of these complications
was observed in patients having versus not having a
kidney pain event, irrespective of treatment arm.
Tolvaptan-induced polyuria, which can be up to 4 to
6 L per day, might explain the lower incidence of
these aforementioned renal complications because
increased water intake is associated with lower
recurrence of kidney stones and urinary tract in-
fections in the general population.16 It may be that
increasing water intake to such an extent without
using tolvaptan could have a similar effect on acute
kidney pain events. However, this has never been
studied, and data in the literature suggest that it is
questionable whether such high spontaneous water
intake is feasible during prolonged periods.17 OurAm J Kidney Dis. 2017;69(2):210-219data indicate that the pain-lowering effect of tolvaptan
might be mediated at least in part by a reduction in
incidence of renal complications known to be asso-
ciated with kidney pain. Of note, 58.8% of the tol-
vaptan group who had a kidney pain event did not
report one of these complications. This suggests that
other yet unidentiﬁed mechanisms may play a role.
For instance, it might well be that tolvaptan reduces
cyst ﬂuid secretion and thereby ﬂuid pressure within
cysts, leading to fewer pain events. Another possible
additional mechanism may be the reﬂex increase in
vasopressin concentration that is observed when the
V2 receptor is blocked by tolvaptan.18,19 Vasopressin
stimulates the secretion of b-endorphins by the hy-
pothalamus, which could cause a central analgesic
effect.20,21
The number needed to treat to prevent one acute
kidney event is high to prescribe tolvaptan to patients
with ADPKD with the sole aim of preventing such
acute kidney pain events and should be weighed
against the fact that in the TEMPO 3:4 trial, patients
who were given tolvaptan had a greater number of
adverse events related to aquaresis (ie, polydipsia,
polyuria, and nocturia)5 and that tolvaptan has a po-
tential hepatotoxic effect. The rates of all observed
adverse events during the 3-year trial were discussed
in more detail in the initial publication.5 Any potential
beneﬁt should of course be weighed against these
disadvantages. In our opinion, the primary aim of
prescribing tolvaptan for patients with ADPKD
therefore remains its renoprotective efﬁcacy. How-
ever, the present analyses indicate that when pre-
scribed, there is an additional beneﬁt that may be
important, especially for patients with ADPKD with
recurrent acute pain events. When considering
whether to prescribe this drug, health care providers
should carefully inform patients about potential risks
and beneﬁts.
There are limitations to our study worth addressing.
First, this study was performed as a post hoc analysis
of a randomized controlled trial. However, the
outcome under study was prespeciﬁed per protocol.
Second, the TEMPO 3:4 study had speciﬁc inclusion
criteria for TKV and eGFR that were deﬁned to enrich
the patient population to be included for rapid disease
progression. This may make extrapolation of our
ﬁndings to the general ADPKD population difﬁcult.
However, neither the incidence of kidney pain events
nor the effect of tolvaptan on kidney pain events was
associated with baseline TKV or eGFR, suggesting
that our results may be valid in the general ADPKD
population. Third, the aquaretic response to tolvaptan
causes polyuria. This may have caused unblinding in
the study, which may have resulted in under- or
overestimation of pain reporting. However, we
assessed kidney pain events deﬁned by objective217
Casteleijn et alcriteria (ie, the need for medical intervention), and
moreover, events were adjudicated by an independent
committee that was blinded for treatment allocation.
Therefore, we consider our data to be robust. Last,
this study focuses on only acute kidney pain events
and did not investigate the effect of tolvaptan on
chronic pain in ADPKD, which is beyond the scope
of the present study. The main strength of this study is
that it was performed in a large population of patients
with ADPKD in several countries across the world,
making it seemingly the most comprehensive study
available that investigates characteristics predisposing
for kidney pain events among patients with ADPKD
in a cross-sectional setting and the ﬁrst study
addressing this question in a longitudinal setting.
Moreover, it describes the effect of tolvaptan as the
ﬁrst disease-modifying drug on kidney pain inci-
dence, another important part of the ADPKD pheno-
type besides TKV growth and eGFR loss.
In conclusion, this study shows that a history of
urinary tract infection, kidney stones, or hematuria
and female sex were associated with a history of
kidney pain at baseline, as well as with incident
kidney pain events during the trial. No association
was found between TKV and history of pain at
baseline or with incident kidney pain events during
the trial, indicating that kidney volume per se did not
play a major role in causing pain. Tolvaptan use was
associated with a lower incidence of acute kidney
pain events in all subgroups deﬁned according to pain
severity and independent of factors predisposing to
pain incidence. The tolvaptan-induced reduction in
incidence of renal complications, such as urinary tract
infections, kidney stones, and hematuria, may at least
in part explain the kidney pain-lowering effect of this
drug.
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